Home >> Tag Archives: Myriad Genetics

Tag Archives: Myriad Genetics

Newsbytes

August 2022—Transfusion medicine specialists at Phoenix Children’s Hospital may be used to trending laboratory biomarkers for sickle cell disease patients in their heads, but a dashboard supporting red blood cell exchange procedures for such patients eases the burden on their cerebral cortices.

Read More »

BRACAnalysis CDx plus Lynparza gets approval

February 2020—Myriad Genetics announced that the FDA has approved BRACAnalysis CDx for use as a companion diagnostic to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor olaparib (Lynparza, AstraZeneca). BRACAnalysis CDx is the first FDA-approved genetic test for this indication, the company reports.

Read More »

FDA approves Myriad MyChoice CDx

January 2020—The FDA has approved Myriad Genetics’ MyChoice CDx for use as a companion diagnostic to identify women with advanced ovarian cancer who are candidates for Zejula (niraparib) in the late-line treatment setting. The FDA also approved the expanded use of Zejula (GlaxoSmithKline) for the treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency.

Read More »

Prolaris test accurately predicts risk of metastasis

October 2019—Myriad Genetics announced publication of results from a study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer (Canter DJ, et al. Prostate Cancer Prostatic Dis. Epub ahead of print June 27, 2019). The pooled analysis included 1,062 men with localized prostate cancer who were definitively treated ...

Read More »

Myriad CDx IDs patients with metastatic pancreatic cancer

August 2019—Myriad Genetics announced that its BRACAnalysis CDx companion diagnostic test effectively identified patients with metastatic pancreatic cancer who benefitted from treatment with olaparib (Lynparza, AstraZeneca) in the phase three POLO study. Results of the study were presented at the 2019 American Society of Clinical Oncology annual meeting in Chicago.

Read More »

BRACAnalysis CDx approved as Talzena companion dx

Oct. 22, 2018—Myriad Genetics announced that the FDA has approved its BRACAnalysis CDx to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP inhibitor, Talzena (talazoparib). Talzena is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast ...

Read More »

Myriad launches EndoPredict, 7/17

July 2017—Myriad Genetics has launched the EndoPredict test in the U.S. for patients with ER+ HER2- early stage breast cancer. EndoPredict is a second-generation test for assessing the 10-year risk of disease recurrence following surgery and for determining which patients can safely forgo adjuvant chemotherapy.

Read More »

myChoice HRD increases eligible patients, 8/16

August 2016—Myriad Genetics announced that its myChoice HRD test successfully identified an increased number of patients with ovarian cancer who may benefit from treatment with niraparib, an investigational oral PARP inhibitor being developed by Tesaro. The announcement follows results of the NOVA study, which evaluated the safety and efficacy of niraparib as a maintenance therapy in more than 500 patients with recurrent ovarian cancer.

Read More »

Myriad Web portal, acquisition, 7/16

July 2016—Myriad Genetics launched a Web portal on ms360.myriad.com that allows patients to access their personal test results and to access other tools and ideas to help them make health care decisions. The first phase of the portal will provide access to test results for the company’s hereditary cancer and prostate cancer tests.

Read More »

Myriad presents Prolaris data at AUA, 7/14

July 2014—Myriad Genetics presented new data from a clinical validation study of Prolaris at the American Urological Association annual meeting in May. A key finding was that the Prolaris molecular diagnostic test accurately differentiated newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower-risk disease. The goal was to validate the Prolaris test score in 761 conservatively managed prostate cancer patients diagnosed by needle biopsy.

Read More »

Myriad Genetics/BioMarin research collaboration, 2/14

February 2014—Myriad Genetics announced a research collaboration with BioMarin that will use Myriad’s novel HRD (homologous recombination deficiency) test to identify tumor types that may be sensitive to BioMarin’s investigational product candidate, BMN-673. Specific terms of the deal, the second research collaboration between the partners, were not disclosed.

Read More »

Test predicts response to cisplatin treatment, 2/14

February 2014—Myriad Genetics presented clinical data from a research study showing that its HRD (homologous recombination deficiency) test predicted platinum response in patients with triple-negative breast cancer (P=0.0003). The HRD score predicted, with a sensitivity of 100 percent, all of the patients who experienced a complete response after presurgical treatment with platinum. In addition, the results showed that the HRD score was generalizable across all breast cancer subtypes.

Read More »

New lung cancer test, 12/13

December 2013—Myriad Genetics launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with early stage lung adenocarcinoma. MyPlan Lung Cancer is an RNA expression panel of 31 cell-cycle-progression genes in combination with tumor staging information to determine a patient’s risk of dying from lung cancer within five years.

Read More »

Hereditary cancer panel, 10/13

Myriad Genetics’ myRisk Hereditary Cancer is a multi-gene diagnostic test that provides increased sensitivity by analyzing 25 genes associated with eight major cancers, including breast, colorectal, ovarian, endometrial, pancreatic, prostate, gastric, and melanoma.

Each test report will include a genetic test result, a clinical risk report, and a health care management tool based on professional society guidelines, providing clear and actionable information to improve patient care regardless of whether the patient receives a positive or negative test result.

Read More »
CAP TODAY
X